Samsung BioLogics Chooses STARLIMS
May 14, 2012
Samsung is willing to improve the development and manufacturing processes of biopharmaceuticals, and reduce the manufacturing cost while keeping top quality and strict regulations required by the pharmaceutical industry.
Samsung is building large scale biopharmaceutical plants with most advanced technologies combining the best practice of existing biopharmaceutical industry and plant design and construction know-how of Samsung.
As of 2013 Samsung BioLogics will offer a broad range of mammalian cell based cGMP manufacturing services for cell line development, process and analytical development, clinical and commercial manufacturing, as well as aseptic fill and finish operations.
To assure ongoing compliance with biologics manufacturing quality standards, Samsung BioLogics chose STARLIMS to be its LIMS provider.
“STARLIMS will provide Samsung its LIMS software to support quality control laboratory testing and for storing and delivering analytical test results,” said Linus Chu, General Manager, STARLIMS Asia Pacific. “STARLIMS passed a thorough audit and evaluation by Samsung BioLogics, which demonstrates our capability to support the business needs of a world class organization that operates a large contract product development and manufacturing facility.”
Samsung BioLogics’s new Incheon facility will manufacture a wide range of biologics products through genetic engineering technologies, cell culturing and purification. “Our biologics facility is capable of producing high quality biopharmaceutical products. We are pleased that our quality control department is relying on STARLIMS leading edge laboratory informatics solutions to help guarantee that all process and final production are top quality, meet global regulatory standards, and maximize customer satisfaction,” said Mingfang Hong, Quality Control Team Leader, Samsung BioLogics.
